Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects

Journal of Endocrinological Investigation

Volumn 36, Issue 7, 2013, Pages 474-477

  Esteghamati, A ^a   Arefzadeh, A ^a   Zandieh, A ^a   Salehi Sadaghiani, M ^a   Noshad, S ^a   Nakhjavani, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Glycemic indices; Normoalbuminuria; Osteoprotegerin; Type 1 diabetes; VEGF

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; OSTEOPROTEGERIN; VASCULOTROPIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; MALE; PROTEIN BLOOD LEVEL; SEX RATIO;

ADULT; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; REGRESSION ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881407235     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03347110     Document Type: Article

References (30)

1. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010, 39: 481-97.
2. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008, 115: 1859-68.
3. Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated hemoglobin level and 16-year incidence of chronic kidney disease in type 1 diabetes. Exp Clin Endocrinol Diabetes 2007, 115: 203-6.
4. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006, 29: 798-804.
5. Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res 2005, 37 (Suppl 1): 90-4.
6. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48: 561-8.
7. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273: 14363-7.
8. BrownerWS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, andmortality in elderly women. J Clin Endocrinol Metab 2001, 86: 631-7.
9. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008, 159: 603-8.
10. Ueland T, Wilson SG, Amirul Islam FM, et al. A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. Clin Endocrinol (Oxf) 2009, 71: 828-33.
11. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudla B. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol 2011, 62: 444-55.
12. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000, 17: 650-6.
13. Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine 2008, 44: 168-71.
14. Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89: 4104-12.
15. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109: 2175-80.
16. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106: 1192-4.
17. Reinhard H, Lajer M, Gall MA, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010, 33: 2561-6.
18. Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and highsensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012, 109: 515-20.
19. Lappin DF, Eapen B, Robertson D, Young J, Hodge PJ. Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. J Clin Periodontol 2009, 36: 634-41.
20. Wang ST, Xu JM, Wang M, Chen FL, Ding G. Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria. Clin Nephrol 2013, 79: 102-8.
21. Galluzzi F, Stagi S, Salti R, et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 2005, 153: 879-85.
22. Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K. Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus. Acta Diabetol 2010, 47: 105-10.
23. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract 2007, 76: 199-206.
24. Grauslund J, Rasmussen LM, Green A, Sjolie AK. Does osteoprotegerin relate to micro- and macrovascular complications in longterm type 1 diabetes? Scand J Clin Lab Invest 2010, 70: 188-93.
25. Vik A, Mathiesen EB, Johnsen SH, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population - the Tromso study. J Thromb Haemost 2010, 8: 898-905.
26. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001, 106: 148-56.
27. Naskret D, Zozulinska-Ziolkiewicz DA, Dankowski R, Wysocki H, Wierusz-Wysocka B. Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients. Microvasc Res 2010, 80: 440-4.
28. Freitas WM, Quaglia LA, Santos SN, et al. Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. Atherosclerosis 2011, 216: 212-6.
29. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis 2009, 19: 521-4.
30. Bello G, Cailotto F, Hanriot D, et al. C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis 2008, 200: 286-93.